Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Open Access

Peer-reviewed

Research Article

The effect of systematic antidepressant treatments in the early stages on sleep and impulsivity in bipolar euthymic patients: A cross-sectional study

  • Mingjin Wang ,

    Roles Data curation, Writing – original draft

    ‡ The two authors share the first authorship.

    Affiliations Tianjin Anding Hospital, Mental Health Center of Tianjin Medical University, Tianjin, China, Tianjin Medical University, Tianjin, China

    ⨯
  • Xuguang An ,

    Roles Data curation, Writing – original draft

    ‡ The two authors share the first authorship.

    Affiliation Tianjin Anding Hospital, Mental Health Center of Tianjin Medical University, Tianjin, China

    ⨯
  • Dongyu Han,

    Roles Formal analysis, Methodology

    Affiliation Tianjin Anding Hospital, Mental Health Center of Tianjin Medical University, Tianjin, China

    ⨯
  • Xiaofei Hou,

    Roles Formal analysis, Methodology

    Affiliation Tianjin Anding Hospital, Mental Health Center of Tianjin Medical University, Tianjin, China

    ⨯
  • Chenghao Yang

    Roles Conceptualization, Funding acquisition, Supervision, Writing – review & editing

    * yts83420@163.com

    Affiliations Tianjin Anding Hospital, Mental Health Center of Tianjin Medical University, Tianjin, China, Tianjin Medical University, Tianjin, China

    ⨯

Abstract

Background and Objectives

Due to early misdiagnosis, bipolar patients who had a depressive episode as their initial onset often received systematic antidepressant treatments and continued to suffer from sleep disturbances and elevated impulsivity, even during euthymic state. The study aims to assess the effect of systematic antidepressant treatments in the early stages on sleep and impulsivity in bipolar euthymic patients, and further explore the potential mediating role of sleep in the relationship between early antidepressant uses and impulsivity.

Methods

A total of 124 bipolar euthymic patients were enrolled. Based on the early use of antidepressants, patients were divided into AT group (systematic antidepressant treatment group) and NT group (no systematic antidepressant treatment group). Sleep quality and impulsivity were assessed using Pittsburgh Sleep Quality Index and Barratt Impulsivity Scale Questionnaire version 11, respectively. Statistical analyses were conducted using the t-test, Chi-square test, and Mann-Whitney U test, and mediation analysis was performed using bootstrapping.

Results

Patients in the AT group showed poorer sleep quality and higher impulsivity than those in the NT group. Patients’ sleep quality was positively correlated with impulsivity. Sleep quality mediated the relationship between antidepressant uses and impulsivity, including both overall impulsivity and non-planning impulsivity.

Conclusions

This study suggests a correlation between early-stage antidepressant use, sleep quality, and impulsivity of bipolar euthymic patients, highlighting the importance of early diagnosis of bipolar disorder and appropriate antidepressant prescriptions. Furthermore, improving sleep quality would be effective in reducing the risk of impulsive behaviors.

Citation: Wang M, An X, Han D, Hou X, Yang C (2025) The effect of systematic antidepressant treatments in the early stages on sleep and impulsivity in bipolar euthymic patients: A cross-sectional study. PLoS One 20(4): e0322274. https://doi.org/10.1371/journal.pone.0322274

Editor: Giuseppe Marano, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Universita' Cattolica del Sacro Cuore, ITALY

Received: November 8, 2024; Accepted: March 19, 2025; Published: April 29, 2025

Copyright: © 2025 Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability: All relevant data are within the paper and its Supporting Information files.

Funding: The work was supported by program of “Research Plan Project of Tianjin Municipal Education Commission” (2022KJ264). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

1. Introduction

Bipolar disorder (BD) is a life-long chronic and disabling disease characterized by recurring, shifting episodes of depression, mania, or hypomania, affecting over 1% of the global population [1]. It is often associated with impaired function and neurocognition [1,2], partially due to dysregulation in sleep and impulsivity [3–5]. According to reports, from the first episode to the diagnosis of BD, there is a delay about 5–10 years or more [6–8]. In clinical practice, approximately 50% of BD patients initially present with a depressive episode and more than 20% are misdiagnosed as major depressive disorder (MDD) [9–11]. Therefore, due to the incorrect or delayed diagnosis, many patients receive routine systematic treatments with antidepressants during the early stages [10,12]. As is well known, the use of antidepressants in treating bipolar depression can eventually lead to several negative outcomes, including accelerated mood switching, irritability, cognitive impairment, and increased suicidal risk [7,13,14]. Notably, the potential effects of antidepressant use in the early phase have not received much attention.

Sleep disturbances commonly occur in individuals with BD and can be present throughout the entire course of the disease [15–17]. Poor sleep quality is comprehensively correlated with depressive, hypomanic, and manic episodes, and changes in sleep patterns are common symptoms [15,18]. Sleep disturbances have been demonstrated to be a significant factor contributing to the low quality of life [16,19,20]. For instance, individuals with poor sleep quality showed deficits in emotion regulation, less positive affect, and increased impulsivity [19,21]. Additionally, as a trait of BD, impulsivity is observed throughout the entire disease course [22,23], resulting in a notable impact on cognitive function and suicide attempts [24,25]. The link between sleep disturbances and impulsivity in bipolar patients has been previously reported; individuals with poor sleep quality are more likely to be impulsive [26–29]. Such correlations are comprehensive and observed across multiple disease cohorts. One study focusing on inpatients with antisocial or borderline personality disorder indicated that sleep problems were significantly related to self-reported impulsivity [26]; and improved sleep duration was associated with statistical reductions in aggressive thoughts and behaviors in adolescents with substance dependence [30]. However, extant research examining the association between sleep quality and impulsivity during the euthymic phase of BD is sparse.

Overall, early diagnosis of BD presents significant challenges, leading to widespread use of antidepressant medications. It is of considerable clinical value to explicitly identify their potential adverse effects. Furthermore, the prevalence of sleep disturbances and increased impulsivity, as well as their effect on social functioning, should receive due attention. Additionally, based on the principles of comprehensive care management, growing interest has focused on abnormalities implicated in the euthymic state of bipolar patients. In this regard, this study aimed to explore the influence of systematic treatment with antidepressants (defined as receiving adequate dosage of antidepressants for at least 6 weeks) in the early stages (defined as a period from initial depressive onset to the diagnosis of BD) on sleep and impulsivity, and to investigate the potential relationship between sleep disturbances and dysregulated impulsivity of bipolar euthymic patients. The goal is to provide guidance for a deeper understanding of antidepressant use in BD patients, as well as for the maintenance treatment of bipolar euthymic patients.

2. Materials and methods

2.1. Setting and subjects

The study consists of 124 bipolar euthymic patients who had experienced a depressive episode as their initial onset. Based on a history of systematic antidepressant treatments in the early stages, patients were consecutively divided into the systematic antidepressant treatment (AT) group and the no systematic antidepressant (NT) group. All patients were aged 18–50, recruited from outpatient and inpatient departments of Tianjin Anding Hospital located in Tianjin, China, during 1st September, 2020 and 30th May, 2023. After approving by the Medical Ethics Committee of Tianjin Anding Hospital, written informed consent from all patients was obtained.

The patients enrolled in this study had already been diagnosed with BD according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV-TR) with Structured Clinical Interview for DSM-IV (SCID). They had been in remission for at least 4 weeks prior to engage in the study. We used the Mini-International Neuropsychiatric Interview (MINI) to retrospectively diagnose the initial depressive episode. All patients were assessed with the Montgomery-Asberg Depression Scale (MADRS) and the Young Mania Rating Scale (YMRS) to determine their euthymic status, with both scores being lower than 7 points [31,32]. The Hypomania Check List-32 items (HCL-32) was administered to screen for potential hypomanic symptoms during the early stages. Patients who had organic mental disorders, mental retardation, personality disorders, cognition impairments, concurrent or a history of substance abuse or dependence, or comorbidity of attention deficit and hyperactivity disorder (ADHD), were excluded. Please refer to the published study protocol for experimental details [33].

2.2. Procedures and clinical assessment

This is a cross-sectional study aimed at exploring the influence of systematic treatment with antidepressants in the early stages on sleep and impulsivity, as well as the mediating role of sleep quality in the relationship between early-stage antidepressant use and impulsivity in bipolar euthymic patients. Two senior psychiatrists initially screened patients according to the inclusion and exclusion criteria. Afterward, all enrolled patients signed informed consent and were divided into the AT and NT groups. In addition, the senior psychiatrists collected other study parameters, including age, sex, ethnicity, age of onset and diagnosis, and a history of mood stabilizer use. The remaining scales were then administered by other investigators, who were blinded to the group assignments. The Pittsburgh Sleep Quality Index (PSQI), a self-rating questionnaire with 18 items, was used to assess sleep disturbances and quality over the past month [34]. Barratt Impulsivity Scale Questionnaire version 11 (BIS-11A) is a self-reported scale used to assess impulsivity [35], consists of 30 questions with a 4-point scale for each response, ranging from 1 to 4. It includes three subscales: attention impulsivity, motor impulsivity, and non-planning impulsivity (Fig 1).

thumbnail
Download:
Fig 1. Study flowchart.

AT, systematic antidepressant treatment; NT, no systematic antidepressant treatment.

https://doi.org/10.1371/journal.pone.0322274.g001

2.3. Statistical analysis

The baseline characteristics of the two groups were compared. The normality of the data was tested using the Shapiro-Wilks test. If the sample was normally distributed, the data was expressed as “mean ± standard deviation”, and the t-test was used to compare continuous variables. The Pearson correlation analysis was performed to examine the bivariate correlations between the variables. If the sample was not normally distributed, the data was expressed as the median (inter-quartile range). The difference between the two groups was compared using the Mann-Whitney U test, and the bivariate correlations between the variables were tested using Spearman correlation analysis. For categorical variables, the Chi-square test was used to analyze the differences between groups.

To explore potential mediating effects, we utilized a bootstrapping technique with Model 4 of the PROCESS macro, version 4.1. To robustly assessing mediation, we generated 5000 bootstrap estimates alongside bias-corrected 95% confidence intervals (CIs). Non-zero CI values indicated a significant mediation effect at the 5% significance level. To control for confounding factors, we adjusted for covariates such as sex, age, years of diagnostic delay, and the use of mood stabilizers in the mediation analysis. All p-values were two-tailed, with statistical significance set at p<0.05. The analyses were conducted using SPSS, version 26.0.

3. Results

3.1. Descriptive statistics

The sociodemographic and clinical characteristics of all 124 participants are presented in Table 1. There was no statistically significant difference between the two groups (p>0.05) in terms of age, sex, years of diagnostic delay, use of mood stabilizers, and scores of MADRS and YMRS. The average PSQI score of the AT group (Mean=8.27) was higher than the NT group (Mean=6.13), and the difference was statistically significant (p<0.001). The participants in the AT group had significantly higher level of impulsivity than those in the NT group. The average impulsivity score was 61.39 (SE=9.429) for the AT group and 57.19 (SE=8.596) for the NT group. The average subscale scores for the AT group were 13.29 (SE=2.939) for attention impulsivity, 23.13 (SE=3.957) for motor impulsivity, and 24.97 (SE=4.949) for non-planning impulsivity. The average subscale scores for the NT group were 12.11 (SE=2.776) for attention impulsivity, 22.39 (SE=3.800) for motor impulsivity, and 22.69 (SE=4.779) for non-planning impulsivity. The scores of attention impulsivity, non-planning impulsivity, and overall impulsivity measured by BIS-11A were significantly different between the two groups (p<0.05), with individuals in the AT group being significantly more impulsive. However, no statistical difference was found in motor impulsivity between the two groups (p>0.05). See Table 2 for details.

thumbnail
Download:
Table 1. Sociodemographic and clinical characteristics.

https://doi.org/10.1371/journal.pone.0322274.t001

thumbnail
Download:
Table 2. Sleeping quality and impulsivity.

https://doi.org/10.1371/journal.pone.0322274.t002

3.2. Preliminary correlation analyses

As shown in Table 3, systematic treatment with antidepressants was positively correlated with the total score of the PSQI (r=0.488, p<0.000), indicating that antidepressant use in the early stages led to worse sleeping quality in bipolar euthymic patients. Furthermore, with the exception of motor impulsivity (r=0.128, p>0.05), a positive correlation was also observed between systematic antidepressant treatment and the scores of BIS-11A (r=0.245, p<0.01), attention impulsivity (r=0.190, p<0.05) and non-planning impulsivity (r=0.228, p<0.05). In other words, antidepressant use in the early stages can significantly elevate the level of impulsivity in bipolar euthymic patients. Finally, sleeping quality, as measured by PSQI, was positively correlated with the strength of impulsivity (r=0.290, p<0.001) and each subtype, including attention impulsivity (r=0.191, p<0.05), non-planning impulsivity (r=0.289, p<0.001), and motor impulsivity (r=0.186, p< 0.05).

thumbnail
Download:
Table 3. Correlations between key study variables.

https://doi.org/10.1371/journal.pone.0322274.t003

3.3. Mediation analyses

The results of the mediation analyses are displayed in Table 4, Fig 2 and Fig 3. Model 1 shows the association between independent variable (systematic antidepressants treatment) and the mediator (sleep quality by PSQI). Model 2 shows the relationship between the independent variable and the dependent variables (scores of BIS-11A, attention impulsivity, and non-planning impulsivity). Model 3 shows the correlation between the independent variable, the mediator and the dependent variables. Both crude and adjusted models are presented. As shown in the crude model, there is a significant association between antidepressant use and PSQI (β=2.145, SE=0.438, p<0.000). In Model 1, after adjusting for sex, age, years of diagnostic delay and use of mood stabilizers, antidepressant use remained significantly associated with PSQI (β=2.177, SE=0.446, p<0.000). Similarly, the associations between antidepressant use and the scores of BIS-11A (β=4.194, SE=1.620, p<0.05), attention impulsivity (β=1.177, SE=0.513, p<0.05), and non-planning impulsivity (β=2.274, SE=0.874, p<0.05) were significant in the crude model. In Model 2, these significant associations remained after adjusting for sex, age, years of diagnostic delay and use of mood stabilizers (BIS-11A: β=4.357, SE=1.613, p<0.05; attention impulsivity: β=1.234, SE=0.516, p<0.05; non-planning impulsivity: β=2.316, SE=0.871, p<0.05). In Model 3, after correcting for sex, age, years of diagnostic delay, and use of mood stabilizers, no significant correlations were found between antidepressant use and the scores of BIS-11A (β=2.701, SE=1.736, p>0.05), attention impulsivity (β=0.971, SE=0.565, p>0.05), or non-planning impulsivity (β=1.426, SE=0.938, p>0.05). The positive correlation between PSQI and attention impulsivity remained statistically insignificant (β=0.121, SE=0.106, p>0.05), while the associations with BIS-11A (β=0.761, SE=0.327, p<0.05) and non-planning impulsivity (β=0.409, SE=0.177, p<0.05) remained statistically significant.

thumbnail
Download:
Table 4. Mediating effect of sleep between antidepressant uses and impulsivity.

https://doi.org/10.1371/journal.pone.0322274.t004

thumbnail
Download:
Fig 2. The crude mediation model of the association of antidepressant uses and impulsivity through sleep quality.

PSQI, Pittsburgh Sleep Quality Index; p* < 0.05, p*** < 0.001 (two-tailed).

https://doi.org/10.1371/journal.pone.0322274.g002

thumbnail
Download:
Fig 3. The adjusted mediation model of the association of antidepressant uses and impulsivity through sleep quality.

PSQI, Pittsburgh Sleep Quality Index; adjusting sex, age, years of diagnostic delay and use of mood stabilizers; p* < 0.05, p*** < 0.001 (two-tailed).

https://doi.org/10.1371/journal.pone.0322274.g003

The total, direct, and indirect effects of the mediation analyses are displayed in Table 5. In the crude model, both the indirect effects of overall impulsivity and non-planning impulsivity were significant because the bootstrap 95% CIs did not contain zero, which suggests that the mediation models were valid. The significance remained even after adjusting for covariates, including sex, age, years of diagnostic delay, and use of mood stabilizers. The mediation analyses indicated that systematic antidepressant treatment in the early stages could increase impulsivity by affecting sleep quality in bipolar euthymic patients.

thumbnail
Download:
Table 5. The results of the mediation analyses.

https://doi.org/10.1371/journal.pone.0322274.t005

4. Discussion

The current study explored the effects of systematic antidepressant treatment in the early stages on sleeping quality and impulsivity, as well as the mediation role of sleeping quality in the relationship between antidepressant use and impulsivity in patients with BD during the euthymic phase. The main findings of this study are as follows: First, participants’ sleep quality was significantly positively correlated with impulsivity; second, systematic antidepressant treatment in the early stages had a noticeably negative influence on sleep and both overall impulsivity and its subtypes; third, the effect of antidepressant use on overall impulsivity and non-planning impulsivity was mediated by sleep quality. To our knowledge, this is the first study to date investigating the correlations between antidepressant use, sleep quality, and impulsivity in bipolar euthymic patients.

Impulsivity, defined as a predisposition toward unplanned reactions to internal or external stimuli and a lack of regard for negative consequences [36], often leads to serious behavioral outcomes, such as violent actions and suicide attempts [37,38]. Impulsivity is observed throughout the course of BD, including during the euthymic state [39,40]. The link between sleep and impulsivity is well-documented, yet studies focusing on both factors in remitted BD patients are sparse. Research indicates that bipolar euthymic patients with poor sleep quality exhibit higher impulsivity, similar to findings by Anda Gershon et al., who showed increased impulsivity in adolescents with BD due to variation in sleep duration [25]. A study by Laura Palagini et al. in bipolar patients with mixed features reaches a unanimous conclusion [41]. Additionally, research across various demographics, including healthy individuals, as well as those with ADHD and substance abuse, shows a significant correlation between sleep disruption and increased impulsivity [3,29,30,42]. Sleep disturbances impact prefrontal cortical functions that are crucial for regulating behavior and emotions [26,43,44], which explains heightened impulsivity in those with poor sleep. Moreover, studies suggest a bi-directional relationship between sleep quality and impulsivity [45–47], offering valuable insights, even though these findings are not directly generalizable from healthy individuals to BD patients. A positive correlation was observed between MADRS and PSQI scores (r=0.307, p＜0.001), excluding MADRS from adjusted confounder analysis. Research suggests a strong bi-directional link between sleep and depression; insomnia is not only a symptom but also a risk factor for depression, and conversely, depression commonly causes insomnia [48,49]. Additionally, Nierenberg et al. reported that sleep issues are prevalent residual symptoms in depressives achieving clinical remission (scores of the Hamilton Depression Rating Scale ≤ 7) [50]. This reciprocal relationship may explain why more severe depressive symptoms correlate with poorer sleep quality during bipolar euthymia.

The use of antidepressants in bipolar depression presents a paradox. About 20%-50% of BD patients intermittently or chronically exhibit subsyndromal symptoms, including subthreshold depression, cognitive impairment, and circadian rhythm disruptions [51–53]. Evidence indicates that antidepressants may increase aggression and impulsivity [54–57], although other studies associate SSRIs with reduced impulsivity [57–59]. It seems that antidepressants can both disrupt and promote sleep [14]. This may be disease status-dependent and also associated with the types and pharmacological mechanisms of the drugs. The comprehensive therapeutic effect of antidepressants is to alleviate depressive symptoms, including both positive and negative affect, which are significantly associated with impulsivity. However, antidepressant medications themselves can induce aggressive symptoms. The current study focused on sleeping quality and impulsivity during the euthymic period, which may be influenced by the antidepressant use in the early stages.

The current study provides the first demonstration that sleep plays a mediating role in the effects of antidepressant use on impulsivity in bipolar euthymic patients. Additionally, compared to previous studies, we specifically describe the relationship between sleep quality and three subtypes of impulsivity. While our results provide valuable insights, there are some limitations that need to be considered. First, the lack of objective measurements of assessing sleep problem and impulsivity, as well as the reliance on self-reported data, may introduce potential bias. Second, the cross-sectional nature of our study design limits our ability to establish causation, restricting our ability to elaborate on temporal relationships between antidepressant use, sleep, and impulsivity. Lastly, other factors may interfere with the study outcomes but were not considered, such as discrepancies in antidepressant types, dosages, and the duration of antidepressant treatment. Future research should incorporate longitudinal observations, utilize objective indicators, and minimize confounding factors to enhance the study’s validity.

Overall, the difficulty in diagnosing BD early and the inconsistent attitude toward the administration of antidepressants to bipolar depressive patients pose intense challenge, which has resulted in an extensive use of antidepressants among individuals with bipolar depression. The conclusions drawn from our research underscore the importance of caution when considering the use of antidepressants in BD patients, even before the manifestation of distinctive symptoms of BD. Furthermore, sleep quality can be targeted as an intervention to mitigate the potential effects of early antidepressant treatment on impulsivity, thereby serving as a compensatory mechanism to reduce impulsive behaviors. The study findings will be beneficial in clinical practice for future applications.

Supporting information

S1 File. Supplementary data.

https://doi.org/10.1371/journal.pone.0322274.s001

(XLSX)

Acknowledgments

We would like to express our gratitude to all the participants for their support and dedication to this study.

References

  1. 1. McIntyre RS, Berk M, Brietzke E, Goldstein BI, López-Jaramillo C, Kessing LV, et al. Bipolar disorders. Lancet. 2020;396(10265):1841–56. pmid:33278937
  2. 2. Clemente AS, Diniz BS, Nicolato R, Kapczinski FP, Soares JC, Firmo JO, et al. Bipolar disorder prevalence: a systematic review and meta-analysis of the literature. Braz J Psychiatry. 2015;37(2):155–61. pmid:25946396
  3. 3. Titone MK, Goel N, Ng TH, MacMullen LE, Alloy LB. Impulsivity and sleep and circadian rhythm disturbance predict next-day mood symptoms in a sample at high risk for or with recent-onset bipolar spectrum disorder: An ecological momentary assessment study. J Affect Disord. 2022;298(Pt A):17–25. pmid:34728283
  4. 4. Dollish HK, Tsyglakova M, McClung CA. Circadian rhythms and mood disorders: Time to see the light. Neuron. 2024;112(1):25–40. pmid:37858331
  5. 5. Huang M-H, Kuan Y-H, Chan Y-LE, Mao W-C, Su T-P. Poor subjective sleep quality and trait impulsivity in patients with bipolar disorder. CNS Spectr. 2024;29(4):289–95. pmid:38708739
  6. 6. Morselli PL, Elgie R, . GAMIAN-Europe/BEAM survey I--global analysis of a patient questionnaire circulated to 3450 members of 12 European advocacy groups operating in the field of mood disorders. Bipolar Disord. 2003;5(4):265–78. pmid:12895204
  7. 7. Shim IH, Woo YS, Kim M-D, Bahk W-M. Antidepressants and Mood Stabilizers: Novel Research Avenues and Clinical Insights for Bipolar Depression. Int J Mol Sci. 2017;18(11):2406. pmid:29137178
  8. 8. Nierenberg A, Agustini B, Köhler-Forsberg O, Cusin C, Katz D, Sylvia L, et al. Diagnosis and treatment of bipolar disorder: A review. JAMA. 2023;330(14):1370–80.
  9. 9. Hu X, Yu C, Dong T, Yang Z, Fang Y, Jiang Z. Biomarkers and detection methods of bipolar disorder. Biosens Bioelectron. 2023;220:114842. pmid:36347076
  10. 10. Tondo L, Vázquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatr Scand. 2010;121(6):404–14. pmid:19958306
  11. 11. Chen L, Xu Y-Y, Lin J-Y, Ji ZP, Yang F, Tan S, et al. The prevalence and clinical correlates of suicide attempts in patients with bipolar disorder misdiagnosed with major depressive disorder: Results from a national survey in China. Asian J Psychiatr. 2024;93:103958. pmid:38364597
  12. 12. Tondo L, Miola A, Pinna M, Contu M, Baldessarini RJ. Antidepressant-associated diagnostic change from major depressive to bipolar disorder. Acta Psychiatr Scand. 2024;150(3):126–37. pmid:38922810
  13. 13. Pacchiarotti I, Bond D, Baldessarini R, Nolen W, Grunze H, Licht R, et al. The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. American Journal of Psychiatry. 2013;170(11):1249–62.
  14. 14. Wichniak A, Wierzbicka A, Walęcka M, Jernajczyk W. Effects of Antidepressants on Sleep. Curr Psychiatry Rep. 2017;19(9):63. pmid:28791566
  15. 15. Keskin N, Tamam L, Ozpoyraz N. Assessment of sleep quality in bipolar euthymic patients. Compr Psychiatry. 2018;80:116–25. pmid:29091777
  16. 16. Esan O, Fela-Thomas A. The significance of sleep quality in euthymic bipolar patients from Nigeria. S Afr J Psychiatr. 2022;28:1739. pmid:35281965
  17. 17. Krane-Gartiser K, Steinan M, Langsrud K, Vestvik V, Sand T, Fasmer O, et al. Mood and motor activity in euthymic bipolar disorder with sleep disturbance. Journal of Affective Disorders. 2016;202:23–31.
  18. 18. Saunders EF, Novick DM, Fernandez-Mendoza J, Kamali M, Ryan KA, Langenecker SA, et al. Sleep quality during euthymia in bipolar disorder: the role of clinical features, personality traits, and stressful life events. Int J Bipolar Disord. 2013;1:16. pmid:25505683
  19. 19. Gold AK, Sylvia LG. The role of sleep in bipolar disorder. Nat Sci Sleep. 2016;8:207–14. pmid:27418862
  20. 20. Giglio LMF, Andreazza AC, Andersen M, Ceresér KM, Walz JC, Sterz L, et al. Sleep in bipolar patients. Sleep and Breathing. 2008;13(2):169-73.
  21. 21. Saksvik-Lehouillier I, Saksvik SB, Dahlberg J, Tanum TK, Ringen H, Karlsen HR, et al. Mild to moderate partial sleep deprivation is associated with increased impulsivity and decreased positive affect in young adults. Sleep. 2020;43(10):zsaa078. pmid:32306048
  22. 22. Chan CC, Alter S, Hazlett EA, Shafritz KM, Yehuda R, Goodman M, et al. Neural correlates of impulsivity in bipolar disorder: A systematic review and clinical implications. Neurosci Biobehav Rev. 2023;147:105109. pmid:36813146
  23. 23. Saddichha S, Schuetz C. Is impulsivity in remitted bipolar disorder a stable trait? A meta-analytic review. Compr Psychiatry. 2014;55(7):1479–84. pmid:25035161
  24. 24. Jiménez E, Arias B, Castellví P, Goikolea J, Rosa A, Fañanás L, et al. Impulsivity and functional impairment in bipolar disorder. J Affective Disord. 2012;136(3):491–7.
  25. 25. Gershon A, Johnson SL, Thomas L, Singh MK. Double trouble: Weekend sleep changes are associated with increased impulsivity among adolescents with bipolar I disorder. Bipolar Disord. 2019;21(2):132–41. pmid:29781205
  26. 26. Van Veen MM, Karsten J, Lancel M. Poor Sleep and Its Relation to Impulsivity in Patients with Antisocial or Borderline Personality Disorders. Behav Med. 2017;43(3):218–26. pmid:28767018
  27. 27. Grant JE, Chamberlain SR. Sleepiness and impulsivity: Findings in non-treatment seeking young adults. J Behav Addict. 2018;7(3):737–42. pmid:30203693
  28. 28. Cavic E, Valle S, Chamberlain SR, Grant JE. Sleep quality and its clinical associations in trichotillomania and skin picking disorder. Compr Psychiatry. 2021;105:152221. pmid:33395591
  29. 29. Huang Y-S, Jan Y. Comorbidity and confounding factors in attention-deficit/hyperactivity disorder and sleep disorders in children. Psychology Research and Behavior Management. 2011.
  30. 30. Haynes PL, Bootzin RR, Smith L, Cousins J, Cameron M, Stevens S. Sleep and aggression in substance-abusing adolescents: results from an integrative behavioral sleep-treatment pilot program. Sleep. 2006;29(4):512–20. pmid:16676785
  31. 31. HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56–62. pmid:14399272
  32. 32. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–35. pmid:728692
  33. 33. Yang H, Liu Y, Yang C, Lin X. The effect of systemic antidepressant treatments in early stage on neurocognitive function of euthymic bipolar patients initiated with a depressive onset: An observational, cross-sectional, single-blind study protocol. Brain Behav. 2021;11(10):e2360. pmid:34520638
  34. 34. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28(2):193–213. pmid:2748771
  35. 35. Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt impulsiveness scale. J Clin Psychol. 1995;51(6):768–74. pmid:8778124
  36. 36. Moeller FG, Barratt ES, Dougherty DM, Schmitz JM, Swann AC. Psychiatric aspects of impulsivity. Am J Psychiatry. 2001;158(11):1783–93. pmid:11691682
  37. 37. Swann AC. Mechanisms of impulsivity in bipolar disorder and related illness. Epidemiol Psichiatr Soc. 2010;19(2):120–30. pmid:20815296
  38. 38. Najt P, Perez J, Sanches M, Peluso MAM, Glahn D, Soares JC. Impulsivity and bipolar disorder. Eur Neuropsychopharmacol. 2007;17(5):313–20. pmid:17140772
  39. 39. Nandagopal JJ, Fleck DE, Adler CM, Mills NP, Strakowski SM, DelBello MP. Impulsivity in adolescents with bipolar disorder and/or attention-deficit/hyperactivity disorder and healthy controls as measured by the Barratt Impulsiveness Scale. J Child Adolesc Psychopharmacol. 2011;21(5):465–8. pmid:22040191
  40. 40. Strakowski SM, Fleck DE, DelBello MP, Adler CM, Shear PK, McElroy SL, et al. Characterizing impulsivity in mania. Bipolar Disord. 2009;11(1):41–51. pmid:19133965
  41. 41. Palagini L, Cipollone G, Masci I, Caruso D, Paolilli F, Perugi G, et al. Insomnia symptoms predict emotional dysregulation, impulsivity and suicidality in depressive bipolar II patients with mixed features. Compr Psychiatry. 2019;89:46–51. pmid:30593973
  42. 42. Beebe DW. Cognitive, behavioral, and functional consequences of inadequate sleep in children and adolescents. Pediatr Clin North Am. 2011;58(3):649–65. pmid:21600347
  43. 43. Anderson C, Platten CR. Sleep deprivation lowers inhibition and enhances impulsivity to negative stimuli. Behav Brain Res. 2011;217(2):463–6. pmid:20888369
  44. 44. Kamphuis J, Dijk D-J, Spreen M, Lancel M. The relation between poor sleep, impulsivity and aggression in forensic psychiatric patients. Physiol Behav. 2014;123:168–73. pmid:24184508
  45. 45. Schmidt RE, Gay P, Ghisletta P, VAN DER Linden M. Linking impulsivity to dysfunctional thought control and insomnia: a structural equation model. J Sleep Res. 2010;19(1 Pt 1):3–11. pmid:19659917
  46. 46. Schmidt RE, Van der Linden M. The aftermath of rash action: sleep-interfering counterfactual thoughts and emotions. Emotion. 2009;9(4):549–53. pmid:19653778
  47. 47. Lowe CJ, Safati A, Hall PA. The neurocognitive consequences of sleep restriction: A meta-analytic review. Neurosci Biobehav Rev. 2017;80:586–604. pmid:28757454
  48. 48. Riemann D, Berger M, Voderholzer U. Sleep and depression--results from psychobiological studies: an overview. Biol Psychol. 2001;57(1–3):67–103. pmid:11454435
  49. 49. Pandi-Perumal SR, Monti JM, Burman D, Karthikeyan R, BaHammam AS, Spence DW, et al. Clarifying the role of sleep in depression: A narrative review. Psychiatry Res. 2020;291:113239. pmid:32593854
  50. 50. Nierenberg A, Keefe B, Leslie V, Alpert J, Pava J, Worthington J, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry. 1999;60(4):221–5.
  51. 51. Roux P, Raust A, Cannavo A-S, Aubin V, Aouizerate B, Azorin J-M, et al. Associations between residual depressive symptoms, cognition, and functioning in patients with euthymic bipolar disorder: results from the FACE-BD cohort. Br J Psychiatry. 2017;211(6):381–7. pmid:29051175
  52. 52. Samalin L, Boyer L, Murru A, Pacchiarotti I, Reinares M, Bonnin CM, et al. Residual depressive symptoms, sleep disturbance and perceived cognitive impairment as determinants of functioning in patients with bipolar disorder. Journal of Affective Disorders. 2017;210:280–6.
  53. 53. Grunze H, Born C. The Impact of Subsyndromal Bipolar Symptoms on Patient’s Functionality and Quality of Life. Front Psychiatry. 2020;11:510. pmid:32595531
  54. 54. Sharma T, Guski LS, Freund N, Gøtzsche PC. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. Bmj. 2016.
    • 55. Molero Y, Lichtenstein P, Zetterqvist J, Gumpert CH, Fazel S. Selective Serotonin Reuptake Inhibitors and Violent Crime: A Cohort Study. PLoS Med. 2015;12(9):e1001875. pmid:26372359
    • 56. Healy D, Herxheimer A, Menkes DB. Antidepressants and violence: problems at the interface of medicine and law. PLoS Med. 2006;3(9):e372. pmid:16968128
    • 57. Keen C, Foulds JA, Willoughby M, Newton-Howes G, Knight J, Fazel S, et al. Antidepressant use and interpersonal violence perpetration: a protocol for a systematic review and meta-analysis. BMJ Open. 2021;11(1):e043306. pmid:33441364
    • 58. Romero-Martínez Á, Murciano-Martí S, Moya-Albiol L. Is Sertraline a Good Pharmacological Strategy to Control Anger? Results of a Systematic Review. Behav Sci (Basel). 2019;9(5):57. pmid:31126061
    • 59. Reist C, Nakamura K, Sagart E, Sokolski KN, Fujimoto KA. Impulsive aggressive behavior: open-label treatment with citalopram. J Clin Psychiatry. 2003;64(1):81–5. pmid:12590628